Study protocol for the development and internal validation of Schizophrenia Prediction of Resistance to Treatment (SPIRIT): a clinical tool for predicting risk of treatment resistance to antipsychotics in first-episode schizophrenia

Saeed Farooq 1,2, Miriam Hattle 2, Paola Dazzan 3,4, Tom Kingstone 1,2, Olesya Ajnakina 3, David Shiers 2,5,6, Maria Antonietta Nettis 6,7, Andrew Lawrence 7, Richard Riley 1,2, Danielle van der Windt 1,2

ABSTRACT

Introduction Treatment-resistant schizophrenia (TRS) is associated with significant impairment of functioning and high treatment costs. Identification of patients at high risk of TRS at the time of their initial diagnosis may significantly improve clinical outcomes and minimise social and functional disability. We aim to develop a prognostic model for predicting the risk of developing TRS in patients with first-episode schizophrenia and to examine its potential utility and acceptability as a clinical decision tool.

Methods and analysis We will use two well-characterised longitudinal UK-based first-episode psychosis cohorts: Aetiology and Ethnicity in Schizophrenia and Other Psychoses and Genetics and Psychosis for which data have been collected on sociodemographic and clinical characteristics. We will identify candidate predictors for the model based on current literature and stakeholder consultation. Model development will use all data, with the number of candidate predictors restricted according to available sample size and event rate. A model for predicting risk of TRS will be developed based on penalised regression, with missing data handled using multiple imputation. Internal validation will be undertaken via bootstrapping, obtaining optimism-adjusted estimates of the model's performance. The clinical utility of the model in terms of clinically relevant risk thresholds will be evaluated using net benefit and decision curves (comparable to competing strategies). Consultation with patients and clinical stakeholders will determine potential thresholds of risk for treatment decision-making. The acceptability of embedding the model as a clinical tool will be explored using qualitative focus groups with up to 20 clinicians in total from early intervention services. Clinicians will be recruited from services in Stafford and London with the focus groups being held via an online platform.

Strengths and limitations of this study

- The proposed study is the first step on the road towards the design and evaluation of a prognostic model and decision tool for the early identification of treatment resistant schizophrenia to aid in shared decision-making and improvement of treatment plans.
- Individual participant data from two existing cohorts will be used to develop and internally validate the prognostic model.
- Using a mixed-method design improves the ability to understand the limitations of the tool in a clinical context and create a foundation to develop it to be more effective.
- A limitation of the development of this tool is that the number of people with treatment-resistant schizophrenia may not be sufficiently large to consider all potential predictors for the model.
- Further testing of the external validity of the prognostic model will be required.

Ethics and dissemination The development of the prognostic model will be based on anonymised data from existing cohorts, for which ethical approval is in place. Ethical approval has been obtained from Keele University for the qualitative focus groups within early intervention in psychosis services (ref: MH-210174). Suitable processes are in place to obtain informed consent for National Health Service staff taking part in interviews or focus groups. A study information sheet with cover letter and consent form are in place. Findings will be shared through peer-reviewed publications, conference presentations and social media. A lay summary will be published on collaborator websites.
INTRODUCTION

Treatment-resistant schizophrenia (TRS) is associated with the highest level of impairment of functioning among mental illnesses and with reduced likelihood of remission and poor adherence to treatment.8 UK estimates for the costs of TRS are not available but considering that almost a third of patients with schizophrenia develop TRS and the total costs for the illness are estimated at about 12 billion pounds a year,3 TRS may be responsible for at least 4 billion pounds in UK. The caregivers for TRS face significant impact on finances, career prospects, social relationships, and sense of freedom leading to frustration and hopelessness.4

The definition of treatment resistance and response in schizophrenia is challenging, but there is broad consensus in the literature that TRS can be defined as lack of response to treatment with at least two different antipsychotics each used for a minimum of 6 weeks.5

There is emerging evidence that TRS may be a categorically different illness subtype from the treatment-responsive schizophrenia. Lally et al6 examined 5-year clinical outcomes in a cohort of 246 patients with first-episode schizophrenia (FES). Treatment resistance was seen in 34% of patients at 5-year follow-up; 70% of which did not respond to antipsychotics from the start of first treatment. In a separate cohort, Demjaha et al7 found that of the patients who were treatment resistant, 84% were treatment resistant from the start. A systematic review that compared baseline characteristics of patients with treatment-resistant and treatment-responsive schizophrenia reported that treatment-resistant patients showed alterations in glutamate and dopaminergic pathways, a lack of dopaminergic abnormalities and significant decreases in grey matter compared with treatment-responsive patients,8 which supported the hypothesis that TRS is a categorically different illness subtype to treatment-responsive schizophrenia.9

The identification of patients at high risk of TRS at the time of initial diagnosis of schizophrenia has the potential to improve clinical outcomes, prevent harm from ineffective treatment and minimise the social and functional disability that results from prolonged psychosis.10 11 as potentially beneficial interventions for TRS are currently not used optimally.12 Treatment with clozapine, the only medication licensed for TRS is often delayed between 5 and 10 years13 14 and is generally prescribed to less than 10% of patients who would benefit from the drug.12 This inadequate use of clozapine is mainly due to mandatory blood testing required for clozapine use, fear of serious side effects, lack of clear guidance on identification of TRS and difficulty in selecting suitable patients.15 Other interventions for TRS such as cognitive behavioural therapy (CBT) are used even less optimally.16

The early identification of those at risk of treatment resistance would minimise the delays to effective treatments for TRS, such as clozapine or CBT, thus preventing the much greater disability and morbidity associated with TRS. A number of potential predictors (prognostic factors) of TRS have been identified that can be measured at the time of diagnosis of a FES. These include poor premorbid functioning, comorbid personality disorder, longer duration of untreated psychosis (DUP), greater severity of negative symptoms, younger age of illness onset, history of serious obstetric complications, perinatal insult and higher level of affective flattening.17–21 Lack of response to antipsychotic medication within the first 2 weeks and lower remission rates at 1 year has also been shown to be strong predictor of subsequent poor response.22 23 A recent systematic review identified the following predictors for TRS in FES: lower premorbid functioning; lower level of education; negative symptoms from first psychotic episode; comorbid substance use; younger age at onset; lack of early response; non-adherence to treatment and longer DUP.24

Prognostic models are used in healthcare to estimate (predict) the risk of future outcomes conditional on the values of multiple predictors (prognostic factors)25 and may guide treatment decisions and prognostic stratification, for example, as proposed in other long-term conditions, including musculoskeletal pain and cancer.25 In these areas, early identification of patients likely to respond well to (or experience least harm from) certain treatments has been shown to result in improved patient outcomes and/or more efficient healthcare.26–29

Previous prognostic models in schizophrenia and related psychosis have been limited to a risk calculator devised for the prediction of psychosis onset20 and a rating scale to predict the long-term outcome of first-episode psychosis.30 A study that aimed to identify individuals with TRS based on genome-wide association data concluded that the use of a polygenic risk score for early identification of TRS is inadequate and not of clinical utility.31 To address this, we propose to develop a prognostic model and develop a clinical tool for identifying patients at risk of TRS at the time of diagnosis of first episode. The model will be based on multiple predictors in combination, including clinical and sociodemographic characteristics. Then, the tool will be defined based on the model predictions and thresholds of risk that define the need for clinical action, as identified by key stakeholders. The tool will support early identification of TRS and shared decision-making regarding alternative treatment options. This paper describes the protocol for our work, which closely follows the PROGnosis RESearch Strategy (PROGRESS) framework and guidance for prognosis research.25 33–36

METHODS AND ANALYSIS

Objectives

Our study objectives are to

► Identify sociodemographic and clinical characteristics likely to be associated with resistance to standard (non-clozapine) antipsychotics drugs in patients with FES.
Develop a prognostic model for estimating an individual’s risk of treatment resistance by 5–10 years based on these characteristics and to undertake internal validation of the model’s predictive performance.

Translate the developed model into a clinical tool and assess its potential acceptability and clinical utility among clinicians working in early intervention in psychosis (EIP) services.

Study design
This will be a mixed-method study. The development of the prognostic model will use individual participant data (IPD) from two existing cohort studies, with statistical methods used to produce the model equation and then to examine the model’s predictive performance in terms of calibration, discrimination and clinical utility. Consultation with patients and clinical stakeholders will be undertaken to agree the potential thresholds of risk for treatment decision-making. The acceptability and perceived utility of the tool will be examined using focus group discussions with clinicians working in EIP services.

Patient and public involvement and engagement
The study has been designed with input from patients and carers. Opportunities for further input to the study are embedded throughout to complement and inform key phases of the research. A patient and carer advisory group comprising 4–6 patients (people with schizophrenia/psychosis) and carers will be established; the group will be chaired by coauthor DS and coordinated by Keele University’s Patient and Public Involvement and Engagement (PPIE) team. Advisory group members will contribute to stakeholder engagement events to ensure the views and opinions of people with schizophrenia/psychosis and their carers are incorporated. A separate clinical expert advisory group will also be established to include local and international experts on schizophrenia to advise on identification of clinical predictors and their relevance in day-to-day clinical practice.

Data sources
IPD from two existing cohorts (Genetics and Psychosis; GAP and Aetiology and Ethnicity in Schizophrenia and Other Psychoses; AESOP-10) will be used to develop and internally validate the prognostic model, based on demographic and clinical characteristics that can be routinely measured in clinical practice. Individually, these cohorts lack the sample size to provide reliable estimates of predictive performance, but in combination the two cohorts offer a rich data set, with an extensive set of candidate predictors and large number of outcome events (cases with TRS). The cohorts have been well described previously.

The follow-up information in the AESOP study was obtained using face-to-face interviews and clinical records; the follow-up assessments in the GAP study were entirely based on review of clinical records. Detailed information has also been collected regarding all treatments received and adherence to treatment and important clinical outcomes, including changes in symptoms over time, hospital admission and death. Further details of the two cohorts are given below.

Start point
Participants at first contact with mental health services for psychosis.

Identification of candidate predictors
We will use an iterative approach to identifying candidate predictors. This will consist of following:

1. We will identify a list of candidate predictors of treatment resistance from available literature, including relevant systematic reviews. Additional focused searches (Medline, EMBASE, PsychINFO) will be carried out to identify additional evidence for candidate predictors.

2. Consultation with our clinical expert and patient advisory group: a group of experts in schizophrenia research is identified and will be consulted. The predictors identified from the literature search will be shared with this group and their views will be sought about the usefulness and validity of these factors in predicting TRS, and whether they can suggest any other potential predictors.

The results of this process will inform the selection of candidate predictors to be considered in the development of the proposed prediction model, restricting to the subset that are available in both data sources for the model development. Additional predictors assumed to be important by our experts and patient advisors but not available in the two data sources can be considered for future updates or improvements of the model, if needed, as new data become available.

Once the set of candidate predictors is established, we will then further consult our clinical expert and patient advisory groups to decide on those to prioritise for inclusion in the prognostic model development (as the total will need to consider sample size restrictions in order to reduce potential for overfitting). This process will use face-to-face (patient advisory group) and videoconference (clinical expert advisory group) meetings, in line with current pandemic restrictions. These meetings will be facilitated by an experienced qualitative researcher, clinical member of the study team and—for the patient advisory group—by the PPIE team member. The advisory groups will be presented with a list of all candidate predictors available in the IPD from two data sets, along with a description of how the predictors have been measured and a brief summary of the existing evidence for their association with resistance to antipsychotic treatment. Discussions will be audio-recorded, and written reports drafted summarising feedback and advice that ranks the predictors by their perceived prognostic importance. The agreed list of candidate predictors will then be taken forward for model development (objective 2).
**Treatment resistance definition**

The definition of TRS varies in different studies, but there is broad consensus in the literature that TRS can be defined as lack of response to treatment with at least two different antipsychotics, each used for a minimum of 6 weeks. This requires treatment with two antipsychotics using a therapeutic dose of each drug in a sequential manner, which is rare in clinical practice for number of reasons. There is usually a delay of up to 5 years in starting the gold-standard treatment for TRS, clozapine. Similar to earlier work conducted in the same geographical regions and in keeping with work from Andreassen et al., remission was defined as the absence of overt psychotic symptoms (operationalised as a score of 2 or 3 on rating scale 2 in the SCAN13; 0=absence, 1=symptom occurred, but fleeting, 2=symptom definitely present, 3=symptom present more or less continuously) for 6 months or longer. This definition of remission was not dependent on the presence of non-psychotic symptoms (eg, depressed mood), nor whether the patients were receiving treatment during remission.

Therefore, in the two data sources for our model development, we define the TRS cases as those who did not respond to two consecutive antipsychotic medication of adequate dose and for an adequate duration and/or the documented reason for switching antipsychotic medication was due to a lack of therapeutic response. An adequate daily dose of antipsychotic medication was defined according to a daily dose of ≥400 mg chlorpromazine equivalence. A gap of no longer than 14 days was allowed between consecutive treatments. We only included as TRS cases those patients who failed to respond and not those who were intolerant of antipsychotic medications or those who self-discontinued antipsychotic medication. Non-response here was measured as not experiencing improvement in symptoms and social functioning in duration of 6 months during the follow-up period.

**Study sample**

**GAP study**

In the GAP cohort, the study sample comprised of participants aged 18–65 meeting criteria for first-episode psychosis disorders (International Classification of Diseases, 10th revision (ICD-10) diagnoses: F20.0, F25.0, F28.0, F29.0). All cases had been admitted to psychiatric inpatient units or seen by community-based mental health teams within the South London and Maudsley (SLaM) National Health Service Foundation Trust between December 2005 and October 2010. The study exclusion criteria were evidence of (1) psychotic symptoms precipitated by an organic cause, (2) evidence of transient psychotic symptoms resulting from acute intoxication as defined by ICD-10, (3) moderate or severe learning disabilities as defined by ICD-10 or (4) head injury causing clinically significant loss of consciousness. Approximately 5 years after first contact with mental health services for psychosis, all patients with a baseline diagnosis of schizophrenia spectrum disorders and who had given consent for follow-up and for their clinical records to be accessed were followed-up. The follow-up data were extracted retrospectively using the electronic psychiatric clinical records (EPCRs). The EPCRs are the primary clinical records keeping system within the SLaM Trust that allows to search all clinical information, including correspondence, discharge letters and events, recorded throughout patients’ journeys through the SLaM Trust services. All deaths and emigrations up to and including those that occurred during the final year of follow-up were identified by a case-tracing procedure with the Office for National Statistics for England and Wales and the General Register Office for Scotland. Overall, 246 out of 283 participants were successfully followed up (86.9%); of these sufficient, information on treatment received was available for 239 cases. Eighty (33.5%) of the cases met criteria for TR and 159 (66.5%) were non-TR.

**Aetiology and Ethnicity in Schizophrenia and Other Psychoses**

AESOP-10 is a 10-year longitudinal, population-based study of incident cases of psychosis from defined catchment areas. At baseline, all patients aged 16–64 years who presented with first-episode psychosis over a 2-year period in centres in southeast London and Nottingham (UK) were invited to take part at approximately 10 years post-inclusion. Out of a total of 557 recruited at baseline 434 participants provided follow-up data (77.8%). For 286 participants for whom there was complete information on medication, adherence to treatment and symptom ratings over the 10-year follow-up period were evaluated. Psychopathology was assessed using the Schedules for Clinical Assessment in Neuropsychiatry. A diagnosis of schizophrenia was made according to ICD-10 diagnostic criteria for research during clinical consensus meetings. Ethical approvals for both cohort studies were obtained from local research ethics committees.

The following variables are recorded in both datasets at baseline: age at first contact with mental health services, gender, ethnicity, baseline diagnosis (IC-10 and DSM), DUP, IQ, educational level, employment status, family history of psychosis, substance abuse, alcohol use, symptoms dimensions, childhood adversity, mode of onset, living arrangements and living alone, being single or separated. To ensure minimal exposure to antipsychotic medications in patients, all assessments were obtained within a 3-month period following the first contact with psychiatric services.

The salient features of the cohort are given in table 1:

**Outcome measures**

For this study, the primary outcome measure will be the occurrence of TRS during the follow-up period, as defined above. We will examine the prediction of treatment resistance by 5–10 years. As the follow-up period is 5 years in GAP and 10 years in AESOP-10, and outcome status is unknown by 5 years (AESOP-10) or 10 years (GAP),
in order to use both data sets for model development, we make the assumption that risks by 5 and 10 years are similar. For complete outcome data, the overall outcome risk is 0.263 across both data sets combined, 0.267 in GAP and 0.259 in AESOP. This reassures us that the data sets and time points are potentially compatible. This will need to be checked in future external validation studies.

Sample size for model development

The combined data set includes 532 (286 AESOP +246 GAP) participants with complete follow-up data, and sufficient information on drug treatment and symptom severity to define treatment resistance across both cohorts, a total of 155 (29%) participants were identified with TRS based on previous studies.7 The number of predictor parameters will be restricted to adhere to this sample size and outcome events (not considering additional statistical power that may arise following inclusion of those with missing TRS values based on multiple imputation). Based on the evidence identified in our literature reviews, we will extract the potential Cox-Snell $R^2$ for models in this field and use it to inform the maximum number of candidate predictor parameters that can be considered for inclusion in the model while minimising overfitting.53 For example, if the Cox-Snell $R^2$ may be about 0.22 for the new model, then up to 15 potential predictor coefficients could be considered, as 15 is the maximum required given the 532 sample size and 29% outcome proportion.53 54 The sample size also ensures that the overall outcome proportion will be estimated precisely, with upper and lower values of the 95% CI within 0.04 of the outcome proportion of 0.29.54

Statistical analysis

Model development and internal validation

Development and internal validation of the prognostic model will be guided by the PROGRESS framework53 34 54 and will be reported adhering to the Transparent Reporting of a multivariable prediction model of Individual Prognosis or Diagnosis (TRIPOD) guidelines.55

First, the extent and distribution of missing data for predictors, treatment characteristics and clinical outcomes will be described. For each cohort, baseline characteristic of participants with complete follow-up data will be described and compared with those who were lost to follow-up in order to assess the risk of attrition bias. Imputation of missing data will be handled separately for each cohort, prior to combining the data for predictive modelling, to retain any potential between-cohort heterogeneity. Imputation of missing data (both outcomes and predictors) will be handled using multiple imputation and Rubin’s rules, under a missing at random assumption, including outcome and candidate predictors in the imputation model alongside a broader set of auxiliary variables available in each cohort (to improve the missing at random assumption).56 57

Next, a model for predicting risk of TRS will be developed based on penalised multivariable regression, considering all candidate predictors emerging from the stakeholder meetings with clinical expert and patient advisory groups, as described above and adhering to the sample size calculation. As there is no censoring in the data sets, we will use logistic regression for occurrence of treatment resistance over the follow-up period (5–10 years).

All predictors chosen for inclusion (adhering to the sample size criteria) will be forced to be included, given the consensus process to identify them as candidate predictors and to remove the potential for instability caused by variable selection methods. Continuous variables will not be categorised and potential non-linear effects will be examined using splines or fractional polynomials.

Apparent performance will be summarised in terms of calibration (calibration plots with smoothed calibration curves; calibration slope and calibration-in-the-large) and discrimination (C-statistic, area under the curve). Then, internal validation will be undertaken using bootstrapping of the entire development data set (accounting for the clustering of participants within studies), to estimate optimism in model performance and to then derived optimism-adjusted estimates of predictive performance for calibration (eg, calibration-in-the-large, calibration slope) and discrimination (C-statistic) of predicted risks. Finally, using the optimism-adjusted calibration slope as a global shrinkage factor, we will shrink (penalise) predictor effects for overfitting. Following this, the intercept term will be re-estimated to ensure calibration-in-the-large.

Between-cohort heterogeneity in baseline risk, predictor effects and the model’s predictive performance will be examined in both apparent and interval validation approaches. This is especially important given the different follow-up time periods in the two data sets (5 and 10 years), and so checking how the model (derived on both datasets combined) performs in each data set separately will help reveal whether predicted and observed risks are similar regardless of whether 5 or 10 years is the time horizon.
Deciding thresholds for treatment decision-making based on the prognostic model

The prediction model will generate the probability (risk) of TRS for individual patients, which in itself (following external validation of predictive performance) will be of future importance to clinicians, patients and their care providers, as it will provide information on prognosis and can inform discussions regarding different treatment options. However, our aim is to use the prognostic model not only for individual risk prediction but also as a clinical decision tool to guide decisions regarding alternative treatment options (eg, start clozapine or continue other antipsychotics) in those at high risk of treatment resistance. This translation will require the identification and agreement of thresholds of predicted risk above which a change in treatment (ie, transfer to clozapine) is warranted and worthwhile, considering the potential benefits, harms (adverse effects) and costs of treatment. For deciding on such thresholds, we will use decision analysis and stakeholder involvement (see below).

Net benefit and decision analysis

Evidence regarding the effects and harms of clozapine therapy for patients with schizophrenia will be extracted from existing (Cochrane) systematic review/meta-analysis evidence. Assuming intervention effects are constant across individuals on a relative scale, those at high risk of TRS are more likely to benefit from treatment in terms of absolute risk reduction than those with low predicted risk of TRS. The thresholds at which clozapine prescription is indicated will need to be determined, based on an assessment of the balance between expected benefits and risks, in consultation with our clinical and patient advisory groups. Using lower thresholds for predicted probabilities will increase sensitivity and miss fewer patients likely to be resistant to first-line antipsychotic treatment, but inevitably means that a larger number of patients without TRS would unnecessarily require treatment with clozapine, and vice versa.

After model development is completed, optimism-adjusted decision curves and net benefit will be calculated to quantify clinical utility across the range of risk thresholds deemed relevant by the advisory group. The scenarios used in this analysis will be based on real-life case descriptions, developed together with our patient and expert advisors (see below). The decision analysis, therefore, will be based on actual clinical and lived experience of TRS and include the social and clinical implications of clozapine use for young individuals when discussing the balance of expected benefits and harms of clozapine therapy compared with first-line antipsychotics or other treatment options. Comparison of net benefit and decision curves for the new tool will be made with other strategies of ‘treat all’ and ‘treat none’.

Consensus exercise with clinical and patient and carer advisors

A workshop will be organised with members of our patient and clinical expert advisory groups and clinicians from local psychiatric intervention services, including about 15 participants. The final prognostic model and its predictive performance will be presented along with results of the decision model. We will use graphics that are accessible to both clinicians and patient representative, in order to illustrate the expected benefits and harms of clozapine at different levels of predicted risk of treatment resistance. We will use an adapted nominal group technique (NGT) as a consensus building exercise to agree optimal thresholds for clozapine prescribing. The NGT is a group process involving problem identification, solution generation and decision-making through ranking or voting that is time-efficient and involves low burden for participants. It allows a rapid process of decision-making, while taking every workshop participant’s opinion into account.

The following issues will be discussed: (1) predictive performance of the model, (2) profiles of subgroups of patients with schizophrenia at varying levels of predicted TRS risk, (3) effect estimates of clozapine at varying levels of predicted TRS risk and (4) balance of benefits, risks and costs of clozapine treatment at varying levels of predicted TRS risk, before achieving consensus regarding proposed thresholds for clozapine prescribing based on the prognostic model. The meetings will be facilitated by an experienced researcher, clinical member of the study team and PPIE team member. Meetings will be audio-recorded and transcribed to ensure that the decision-making process is captured, including the different views prior to agreement regarding each factor.

Evaluating acceptability and clinical utility of clinical decision tool

The acceptability and anticipated clinical usefulness of the clinical tool will be assessed using focus groups with clinicians in EIP services. Focus groups provide a useful means of facilitating discussion between participants to explore specific issues in health research. Qualitative focus groups will be conducted with up to 20 participants (in total; between 6 and 10 per group). Potential participants will be invited based on the following criteria: (1) a qualified psychiatrist; (2) work in early intervention services or in-patients with responsibility for admission of early psychosis patients and (3) are involved in the diagnosis and management of schizophrenia. Potential participants will be identified through local EIP services in Stafford and London. Potential participants will be sent an information sheet and ‘consent to further contact’ form to complete and return to the research team. A date will then be arranged at a convenient location for the participants (eg, NHS site). A one-to-one interview will be offered as an alternative to a focus group to support flexibility.

Informed consent will be obtained at the start of the focus group, which will be digitally recorded. Demographic information will be collected to support description of the participants, including: sociodemographic characteristics, number of years’ experience as a psychiatrist, location of practice and number of patients with
schizophrenia. An experienced qualitative researcher will facilitate the focus group using a semistructured topic guide. Participants will be asked for their views on TRS and their clinical approach to managing TRS. Participants will also be asked to give their views on two case vignettes that describe the characteristics of patients at low and high risk of predicted TRS, including the results of the clinical prediction tool and linked treatment recommendations (based on the results from the workshop with our patient and expert advisory groups). The two vignettes will be sent to the participants prior to the focus group. The following topics will be explored through discussion among participants: content of the tool and wording of items; usefulness of the clinical scale in clinical practice to assess TRS; usefulness of the tool to guide shared decision-making regarding treatment; acceptability to service users; methods of implementing the tool in clinical practice (paper or electronic, linkage to medical records); need for instructions.

Qualitative analysis and codesign of the clinical decision tool

Digital recordings from the focus groups will be transcribed verbatim for analysis. Thematic analysis will be conducted to identify and explore important themes from the data. The qualitative researcher will lead analysis with clinical and non-clinical members of the research team, and input from the PPIE study team member, contributing to the interpretation of data through analysis meetings; this mixed team collaborative approach helps to support the trustworthiness of the finding. The qualitative findings will then be discussed during a workshop with members of our patient and clinical expert advisory groups (n=10 participants), and a final version of the tool, including optimal ways for dissemination and implementation will be agreed. A proposal for further validation and impact analysis will be developed, aiming to investigate the impact of using the tool on patient outcomes and costs of care.

The above process will result in (1) an agreed clinical tool for assessing treatment resistance in FES that may be used to support decisions regarding transition to treatment with clozapine for those at high risk, (2) information on potential acceptability and clinical utility of the tool in terms of net benefit (over other strategies such as treat all and treat none), (3) suggestions for dissemination and implementation in routine clinical practice; (4) recommendations for future research aiming towards further validation of the tool and investigation of clinical and cost-effectiveness of using the tool in the management of FES.

ETHICS AND DISSEMINATION

Obtaining approvals

The development of the prognostic model will be based on anonymised data from the existing AESOP and GAP cohorts, for which ethical approval is in place. Ethical approval has been obtained from Keele University for the qualitative focus groups with EIP services (ref: MH-210174). Suitable processes are in place to obtain informed consent for NHS staff taking part in interviews or focus groups. A study information sheet with cover letter and consent form have been prepared and approved by the local Research Ethics Committee.

The current status of the study

The study has suffered delays due to COVID-19 situation and now planned completion of data collection (including focus groups) is 31 March 2022. The final data sets for developing the model were established after combining the data from two cohorts. The analysis based on these data sets is conducted and a preliminary prediction model is developed, with further sensitivity analyses and internal validation ongoing. The focus groups with clinicians and stakeholders’ consultations are being planned and will be conducted soon.

Dissemination and impact

All outputs will be produced in consultation with service users. The proposed research will include two outputs: (1) a prediction model designed to estimate the probability of TRS using information available at the time of diagnosis of schizophrenia and (2) a clinical decision tool, that is, the prediction model plus an agreed set of thresholds to offer clozapine rather than first-line antipsychotics, including balance of expected costs, benefits and harms of clozapine therapy at these thresholds. The results of the study will be reported in peer-reviewed scientific journals, presented at major national and international conferences and loaded on our websites (Keele and King’s College). Lay summaries will be prepared in collaboration with our PPIE representatives (patient advisory groups) and disseminated through our website, and social media, via our dedicated and widely followed Twitter and Facebook feeds. The team has strong links with professional organisations and networks (eg, The Royal College of Psychiatrists and IEPA, an international organisation of EIP). These will be used for further dissemination of our findings.

DISCUSSION

The clinical tool to predict treatment resistance in schizophrenia will be a significant advance in management of schizophrenia and developing prognosis research in schizophrenia. The proposed study is the first step on the road towards the design and evaluation of a prognostic model and decision tool for the identification and management of TRS. The model will allow the probability (risk) of TRS to be estimated for an individual patient, which in itself could be informative to clinicians, patients and their care providers in shared decision-making. In particular, by providing information about likely prognosis with antipsychotics for treatment after diagnosis with First Rank Symptoms and can inform discussions regarding different or additional treatment options.
WHO framework of prevention of mental disorders proposes primary prevention seeks to prevent the onset (incidence) of a disorder or illness while secondary prevention seeks to lower the rate of established cases of the disorder or illness in the population. Both are prohibitively difficult in psychiatric disorders in view of the limited predictive strength of all known risk factors for mental disorders. For example, testing positive for high risk for psychosis has been found to be associated with a 6% lifetime risk of actually developing psychosis. This means that 94% of those who score positive will not develop psychosis in their lifetime. Preventive interventions for such a small proportion of at risk population will be ethical and economically challenging. Tertiary prevention aims to reduce disability and enhance rehabilitation in long-term and chronic condition. Successful development of Schizophrenia Prediction of Resistance to Treatment will result in early identification of people with schizophrenia who are not likely to respond to standard antipsychotics. This can potentially prevent a debilitating and chronic psychosis in the form of TRS and present an opportunity for tertiary prevention.

Further development and testing of the tool will depend on the actual results of the project. If the results of the proposed study show that the model has good predictive performance, we propose testing of the external validity of the prognostic model (in regards to both 5 and 10-year outcomes) and confirmation of decision thresholds. The generalisability of the predictive model resulting from the present data sets will be limited as the participants recruited in the cohorts mainly consist of urban and white population. To enhance the clinical utility of the proposed model, future studies will be needed in ethnically and economically diverse populations. We are using only clinical variables in the proposed predictive model for use in routine clinical practice, as these are easy to identify and apply in different clinical settings, including those with limited access to expensive laboratory or imaging. In future, other predictors such as such as biochemical and neurobiological variables could be used along with clinical variables tested in our model to enhance the utility of the predictive tool.

After further validation, the prognostic model and linked decision tool could potentially identify patients who would benefit from interventions for TRS at the earliest possible stage, thus improving the quality of health services with potential reduction in overall costs. This will help to reduce symptoms, overall morbidity and improve the quality of life. One possibility is to use the tool along with an algorithm-based approach for early use of clozapine in First Episode Psychosis, as suggested by Agid et al. Early identification and treatment for TRS can potentially lead to other wide-ranging positive outcomes, including increased awareness, improvements in relationships and greater employment.

The involvement of service users in the study will improve the participants' understanding of research in TRS and raise general public awareness which will guide people to seek early clinical help for their mental health problems.

If study aims are met, the research will inform the methodology for prognosis research in early psychosis and psychiatry in general. It will also contribute to the development of research aiming to target effective treatment at the earliest possible stage of schizophrenia, possibly triggering future research such as a full-impact analysis study (eg, cluster-Randomised Control Trial, or large comparative observational study) to investigate the clinical and cost-effectiveness of using the decision tool on patient outcomes and costs of care.

**Author affiliations**

1. Midlands Partnership NHS Foundation Trust, Stafford, UK
2. School of Medicine, Keele University, Keele, UK
3. Department of Biostatistics & Health Informatics, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK
4. Department of Behavioural Science and Health, Institute of Epidemiology and Health Care, University College London, London, UK
5. Psychosis Research Unit, Greater Manchester Mental Health NHS Trust, Manchester, UK
6. Division of Psychology and Mental Health, University of Manchester, Manchester, UK
7. Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, University of London, London, UK

**Twitter** Maria Antonietta Nettis @EttaNettis

**Contributors** SF, PD, OA, DS, RR, DvdW, AL and TK were involved in the original conception and design of the research. All authors SF, MH, PD, TK, OA, DS, MAN, RR, DvdW and AL have contributed to the drafting of this manuscript.

**Funding** This study is supported by NIHR Research for Patient Benefit Programme grant number [NIHR 200510]. OA is funded by an NIHR Post-Doctoral Fellowship (PDF-2018-11-ST2-020).

**Competing interests** DS is expert advisor to the NICE centre for guidelines. The views expressed are the authors’ and not those of NICE.

**Patient and public involvement** Patients and/or the public were involved in the design, or conduct, or reporting, or dissemination plans of this research. Refer to the Methods section for further details.

**Patient consent for publication** Not applicable.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

**ORCID iDs**

Saeed Farooq http://orcid.org/0000-0003-2088-6876
Tom Kingstone http://orcid.org/0000-0001-9179-2303
Maria Antonietta Nettis http://orcid.org/0000-0002-5401-8391
Richard Riley http://orcid.org/0000-0001-8699-0735
Danielle van der Windt http://orcid.org/0000-0002-7248-6703

**REFERENCES**

1. Iasevoli F, Giordano S, Ballestra R, et al. Treatment resistant schizophrenia is associated with the worst community functioning among severely-ill highly-disabling psychiatric conditions and is the most relevant predictor of poorer achievements in functional milestones. Prog Neuropsychopharmacol Biol Psychiatry 2016;65:34–48.
2. Ascher-Svanum H, Nyhuis AW, Faries DE, et al. Clinical, functional, and economic ramifications of early nonresponse to antipsychotics
in the naturalistic treatment of schizophrenia. Schizophr Bull 2008;34:1163–71.

3 Andrews A, Knapp M, McCrone P. Effective interventions in schizophrenia the economic case: a report prepared for the Department of Health. London: National Institute for Health and Care Excellence, 2008.

4 Brain C, Kynes S, DiBenedetti DB, et al. Experiences, attitudes, and perceptions of caregivers of individuals with treatment-resistant schizophrenia: a qualitative study. BMC Psychiatry 2018;18:253.

5 Howes OD, McCutcheon R, Agid O, et al. Treatment-Resistant schizophrenia: treatment response and resistance in psychosis (TRIRIP) Working group consensus guidelines on diagnosis and terminology. Am J Psychiatry 2017;174:216–29.

6 Lally J, Ajnakina O, Di Forti M, et al. Two distinct patterns of treatment resistance: clinical predictors of treatment resistance in first-episode schizophrenia spectrum psychoses. Psychol Med 2016;46:3231–40.

7 Demjaha A, Lappin JM, Stahl D, et al. Antipsychotic treatment resistance in first-episode psychosis: prevalence, subtypes and predictors. Psychol Med 2017;47:1981–9.

8 Gillespie AL, Samanraite R, Mill J, et al. Is treatment-resistant schizophrenia categorically distinct from treatment-responsive schizophrenia? A systematic review. BMC Psychiatry 2017;17:12.

9 Farooq S, Agid O, Foussias G, et al. Using treatment response to subtype schizophrenia: proposal for a new paradigm in classification. Schizophr Bull 2013;39:1169–72.

10 Wheeler A, Humberstone V, Robinson G. Outcomes for schizophrenia patients with clozapine treatment: how good does it get? J Psychopharmacol 2009;23:957–65.

11 Stroup TS, Gerhard T, Crystal S, et al. Comparative effectiveness of clozapine and standard antipsychotic treatment in adults with schizophrenia. Am J Psychiatry 2016;173:166–73.

12 Farooq S, Taylor M. Clozapine: dangerous orphan or neglected Friend? Br J Psychiatry 2011;198:247–9.

13 Wheeler AJ. Treatment pathway and patterns of clozapine prescribing for schizophrenia in New Zealand. Ann Pharmacother 2008;42:582–60.

14 Taylor DM, Young C, Paton C. Prior antipsychotic prescribing in patients currently receiving clozapine: a case note review. J Clin Psychopharmacol 2003;23:40–4.

15 Farooq S, Chouinard A, Cohen D, et al. Barriers to using clozapine in treatment-resistant schizophrenia: systematic review. BJPsychi Bull 2019;43:8–16.

16 Berry K, Haddock G. The implementation of the NICE guidelines for schizophrenia: barriers to the implementation of psychological interventions and recommendations for the future. Psychol Psychother 2008;81:419–36.

17 Jäger M, Riedel M, Messer T, et al. Psychopathological characteristics and treatment response of first episode compared with multiple episode schizophrenia disorders. Eur Arch Psychiatry Clin Neurosci 2007;257:47–53.

18 Meltzer HY, Rabinsvitz J, Lee MA, et al. Age at onset and gender of schizophrenic patients in relation to neuroleptic resistance. Am J Psychiatry 1997;154:747–52.

19 Schennach R, Riedel M, Musil R, et al. Treatment response in First-episode schizophrenia. Clin Psychopharmacol Neurosci 2012;10:78–87.

20 Ortiz BB, Araujo Filho GMde, Araripe Neto AGda, et al. Is disorganized schizophrenia a predictor of treatment resistance? Evidence from an observational study. Braz J Psychiatry 2013;35:432–4.

21 Wimberley T, Stovring H, Sørensen HJ, et al. Predictors of treatment resistance in patients with schizophrenia: a population-based cohort study. Lancet Psychiatry 2016;3:358–66.

22 Correll CU, Malhotra AK, Kauksh S, et al. Early prediction of antipsychotic response in schizophrenia. Am J Psychiatry 2003;160:2063–5.

23 Samara MT, Leucht C, Leeflang MM, et al. Early improvement as a predictor of later response to antipsychotics in schizophrenia: a diagnostic test review. Am J Psychiatry 2014;172:617–29.

24 Bozzatello P, Bellina S, Rocca P. Predictive factors of treatment resistance in first episode of psychosis: a systematic review. Front Psychiatry 2019;10:67.

25 Riley RD, Van der Windt DA, Croft PR. Prognosis research in healthcare: concepts, methods and impact. Oxford University Press, 2019.

26 Williams C, Brunskill S, Altman D, et al. Cost-Effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy. Health Technol Assess 2006;10:i-ix, ix-xi, 1–204.

27 Hill JC, Whitehurst DGT, Lewis M, et al. Comparison of stratified primary care management for low back pain with current best practice (start back): a randomised controlled trial. Lancet 2011;378:1560–71.

28 Foster NE, Mullis R, Hill JC, et al. Effect of stratified care for low back pain in family practice (impact back): a prospective population-based randomized controlled trial. Ann Fam Med 2014;12:102–11.

29 Whitehurst DGT, Bryan S, Lewis M, et al. Exploring the cost-utility of stratified primary care management for low back pain compared with current best practice within risk-defined subgroups. Ann Rheum Dis 2012;71:1796–802.

30 Fusan-Pol I, Rigatol G, Stahl D, et al. Development and validation of a clinically based risk calculator for the Transdiagnostic prediction of psychosis. JAMA Psychiatry 2017;74:493–500.

31 Flyckt L, Mattsson M, Edman G, et al. Predicting 5-year outcome in first-episode psychosis: construction of a prognostic rating scale. J Clin Psychiatry 2006;67:916–24.

32 Wimberley T, Gasse C, Meier SM, et al. Polygenic risk score for schizophrenia and treatment-resistant schizophrenia. Schizophr Bull 2017;43:1064–9.

33 Hemingway H, Croft P, Perel P, et al. Prognosis research strategy (progress) 1: a framework for researching clinical outcomes. BMJ 2013;346:e5955.

34 Riley RD, Hayden JA, Steyerberg EW, et al. Prognosis research strategy (progress) 2: prognostic factor research. PLoS Med 2013;10:e1001380.

35 Steyerberg EW, Moons KGM, van der Windt DA, et al. Prognosis research strategy (progress) 3: prognostic model research. PLoS Med 2013;10:e1001381.

36 Hingorani AD, Windt DA, Vander, Riley RD, et al. Prognosis research strategy (progress) 4: stratified medicine research. BMJ 2013;346:f2.

37 Fearon P, Kirkbride JB, Morgan C, et al. Incidence of schizophrenia and other psychoses in ethnic minority groups: results from the MRC AESOP study. Psychol Med 2006;36:1541–50.

38 Morgan C, Lappin J, Heslin M, et al. Reappraising the long-term course and outcomes of psychotic disorders: the AESOP-10 study. Psychol Med 2014;44:2713–26.

39 Murray RM, Mondelli V, Stillo SA, et al. The influence of risk factors on the onset and outcome of psychosis: what we learned from the gap study. Schizophr Res 2020;256:83–8.

40 Ajnakina O, Lally J, Di Forti M, et al. Patterns of illness and care over the 5 years following onset of psychosis in different ethnic groups; the GAP-5 study. Soc Psychiatry Psychiatr Epidemiol 2017;52:1101–11.

41 Lieberman J, Jody D, Geisler S, et al. Time course and biologic correlates of treatment response in first-episode schizophrenia. Arch Gen Psychiatry 1993;50:369–76.

42 Perkins D, Lieberman J, Gu H, et al. Predictors of antipsychotic treatment response in patients with first-episode schizophrenia, schizoaffective and schizophreniform disorders. Br J Psychiatry 2010;197:1–6.

43 Kinon BJ, Chen L, Ascher-Svanum H, et al. Predicting response to atypical antipsychotics based on early response in the treatment of schizophrenia. Schizophr Res 2008;102:230–40.

44 Carbon M, Correll CU. Clinical predictors of therapeutic response to antipsychotics in schizophrenia. Dialogues Clin Neurosci 2014;16:505–24.

45 Revier CJ, Reininghaus U, Dutta R, et al. Ten-Year outcomes of First-Episode psychoses in the MRC AESOP-10 study. J Nerv Ment Dis 2015;203:179–86.

46 Andreassen NC, Carpenter WT, Kane JM, et al. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry 2005;162:441–9.

47 Ajnakina O, Agedjo D, Lally J, et al. Predicting onset of early- and late-treatment resistance in first-episode schizophrenia patients using advanced shrinkage statistical methods in a small sample. Psychiatry Res 2020;294:113527.

48 Ajnakina O, Das T, Lally J, et al. Structural covariance of cortical gyriﬁcation at illness onset in treatment resistance: a longitudinal study of First-Episode psychoses. Schizophr Bull 2021;47:1729–1739.

49 Ajnakina O, Trotta A, Forti MD, et al. Different types of childhood adversity and 5-year outcomes in a longitudinal cohort of first-episode psychosis patients. Psychiatry Res 2018;269:199–206.

50 Leucht S, Samara M, Heres S, et al. Dose equivalents for second-generation antipsychotics: the minimum effective dose method. Schizophr Bull 2014;40:314–26.

51 World Health Organisation. The ICD-10 classification of mental and behavioural disorders: clinical descriptions and diagnostic guidelines. Geneva, 1992.

52 World Health Organization. Schedules for clinical assessment in psychiatry version 2: manual. World Health organization. Geneva: Division of Mental Health, 1994.
53 Riley RD, Ensor J, Snell KIE, et al. Calculating the sample size required for developing a clinical prediction model. BMJ 2020;368:m441.
54 Riley RD, Snell KI, Ensor J, et al. Minimum sample size for developing a multivariable prediction model: PART II - binary and time-to-event outcomes. Stat Med 2019;38:1278–96.
55 Collins GS, Reitsma JB, Altman DG, et al. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. BMJ 2015;350:g7594.
56 Moons KGM, Donders RART, Stijnen T, et al. Using the outcome for imputation of missing predictor values was preferred. J Clin Epidemiol 2006;59:1092–101.
57 Sterne JAC, White IR, Carlin JB, et al. Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls. BMJ 2009;338:b2393.
58 Okhuijsen-Pfeifer C, Huijsman EAH, Hasan A, et al. Clozapine as a first- or second-line treatment in schizophrenia: a systematic review and meta-analysis. Acta Psychiatr Scand 2018;138:281–8.
59 Barber S, Olotu U, Corsi M, et al. Clozapine combined with different antipsychotic drugs for treatment-resistant schizophrenia. Cochrane Database Syst Rev 2017;3:CD006324.
60 Siskind D, McCartney L, Goldschlager R, et al. Clozapine V. first- and second-generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysis. Br J Psychiatry 2016;209:385–92.
61 Vickers AJ, Van Calster B, Steyerberg EW. Net benefit approaches to the evaluation of prediction models, molecular markers, and diagnostic tests. BMJ 2016;25:i6.
62 Waggoner J, Carlile JD, Durning SJ. Is there a consensus on consensus methodology? Descriptions and recommendations for future consensus research. Acad Med 2016;91:663–8.
63 Harvey N, Holmes CA. Nominal group technique: an effective method for obtaining group consensus. Int J Nurs Pract 2012;18:188–94.
64 Green J, Thorogood N. Qualitative methods for health research. Sage Publications, 2018.
65 Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol 2006;3:77–101.
66 Fernald DH, Duclos CW. Enhance your team-based qualitative research. Ann Fam Med 2005;3:360–4.
67 World Health Organisation. Prevention of mental disorders: effective interventions and policy options. Geneva, 2004.
68 Cuijpers P, Smit F, Furukawa TA. Most at-risk individuals will not develop a mental disorder: the limited predictive strength of risk factors. World Psychiatry 2021;20:224–5.
69 Fusar-Poli P, Cappucciati M, Rutigliano G, et al. At risk or not at risk? A meta-analysis of the prognostic accuracy of psychometric interviews for psychosis prediction. World Psychiatry 2015;14:322–32.
70 Agid O, Remington G, Kapur S, et al. Early use of clozapine for poorly responding first-episode psychosis. J Clin Psychopharmacol 2007;27:369–73.